| Product Name | Tanespimycin (Synonyms: 17-AAG; NSC 330507; CP 127374;KOS-953; KOS 953) |
|---|---|
| CAS | 75747-14-7 |
| Formula | C31H43N3O8 |
| MW | 585.69 |
| MDL | MFCD04973892 |
| Appearance | Purple to purplish red powder |
| Storage condition | 4°C, protect from ligh |
| Size | Availability | Price(USD) | VIP Price (USD) | Quantity |
|---|---|---|---|---|
| 10 mg | 3-5 days | ¥536.00 | Visible after login | |
| 25 mg | 3-5 days | ¥858.00 | Visible after login | |
| 50 mg | 3-5 days | ¥1366.00 | Visible after login |
| Product Name | Tanespimycin (Synonyms: 17-AAG; NSC 330507; CP 127374;KOS-953; KOS 953) |
|---|---|
| CAS | 75747-14-7 |
| Formula | C31H43N3O8 |
| MW | 585.69 |
| MDL | MFCD04973892 |
| Appearance | Purple to purplish red powder |
| Storage condition | 4°C, protect from ligh |
Tanespimycin (17-AAG, CP127374, NSC-330507, KOS 953) is a potent HSP90 inhibitor with IC50 of 5 nM in a cell-free assay, having a 100-fold higher binding affinity for HSP90 derived from tumour cells than HSP90 from normal cells. Tanespimycin (17-AAG) induces apoptosis, necrosis, autophagy and mitophagy.
PMID: 23886587 DOI: 10.1016/j.ejca.2013.06.034
PMID: 22955701 DOI: 10.1007/s10238-012-0208-3
HSP90 Inhibitor 17-AAG Selectively Eradicates Lymphoma Stem Cells.
PMID: 22751135 PMCID: PMC3443561 DOI: 10.1158/0008-5472.CAN-11-3600